1.10
price down icon3.51%   -0.04
after-market Dopo l'orario di chiusura: 1.08 -0.02 -1.82%
loading
Precedente Chiudi:
$1.14
Aprire:
$1.13
Volume 24 ore:
54,174
Relative Volume:
0.26
Capitalizzazione di mercato:
$33.19M
Reddito:
-
Utile/perdita netta:
$-60.70M
Rapporto P/E:
-0.5392
EPS:
-2.04
Flusso di cassa netto:
$-61.05M
1 W Prestazione:
+0.92%
1M Prestazione:
+1.85%
6M Prestazione:
-12.00%
1 anno Prestazione:
-58.49%
Intervallo 1D:
Value
$1.10
$1.13
Intervallo di 1 settimana:
Value
$1.085
$1.15
Portata 52W:
Value
$0.87
$2.7311

An 2 Therapeutics Inc Stock (ANTX) Company Profile

Name
Nome
An 2 Therapeutics Inc
Name
Telefono
(650) 331-9090
Name
Indirizzo
1800 EL CAMINO REAL, SUITE D, MENLO PARK
Name
Dipendente
36
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
ANTX's Discussions on Twitter

Confronta ANTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ANTX
An 2 Therapeutics Inc
1.10 34.40M 0 -60.70M -61.05M -2.04
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-08-09 Downgrade Evercore ISI In-line → Underperform
2024-08-09 Downgrade Leerink Partners Outperform → Market Perform
2024-07-03 Aggiornamento Leerink Partners Market Perform → Outperform
2024-04-02 Aggiornamento JMP Securities Mkt Perform → Mkt Outperform
2024-02-13 Downgrade Leerink Partners Outperform → Market Perform
2024-02-12 Downgrade Evercore ISI Outperform → In-line
2024-02-12 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2024-02-12 Downgrade Oppenheimer Outperform → Perform
2024-01-04 Iniziato JMP Securities Mkt Outperform
2022-07-18 Ripresa Oppenheimer Outperform
Mostra tutto

An 2 Therapeutics Inc Borsa (ANTX) Ultime notizie

pulisher
Jul 16, 2025

Cognition Therapeutics, Inc. Reports Promising Results for Zervimesine in Phase 2 Alzheimer’s and Dementia with Lewy Bodies Studies - Nasdaq

Jul 16, 2025
pulisher
Jul 16, 2025

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC - GlobeNewswire

Jul 16, 2025
pulisher
Jul 15, 2025

Ovid Therapeutics (NASDAQ:OVID) Stock Price Down 2% – Time to Sell? - Defense World

Jul 15, 2025
pulisher
Jul 10, 2025

Cognition Therapeutics, Inc. Discusses Phase 2 Results and Future Plans for Zervimesine Treatment in Alzheimer's Disease with FDA - Nasdaq

Jul 10, 2025
pulisher
Jul 10, 2025

Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease - GlobeNewswire

Jul 10, 2025
pulisher
Jul 10, 2025

Breakthrough for Alzheimer's Treatment: FDA Meeting Clears Path for Zervimesine Phase 3 Program - Stock Titan

Jul 10, 2025
pulisher
Jul 08, 2025

Unicycive Therapeutics (NASDAQ:UNCY) Trading 2% Higher – Time to Buy? - Defense World

Jul 08, 2025
pulisher
Jul 07, 2025

Apogee Therapeutics Announces Positive 16-Week Data from - GlobeNewswire

Jul 07, 2025
pulisher
Jul 07, 2025

New Atopic Dermatitis Drug Shows Record-Breaking 67% Success Rate, Could Reduce Injections to Just 4 Times Per Year - Stock Titan

Jul 07, 2025
pulisher
Jul 07, 2025

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II) - Yahoo Finance

Jul 07, 2025
pulisher
Jul 04, 2025

Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial Data - Benzinga

Jul 04, 2025
pulisher
Jul 03, 2025

Alembic Pharmaceuticals up 2% as arm acquires Utility Therapeutics; details - Business Standard

Jul 03, 2025
pulisher
Jul 01, 2025

Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat - Insider Monkey

Jul 01, 2025
pulisher
Jun 30, 2025

Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program - Yahoo Finance

Jun 30, 2025
pulisher
Jun 27, 2025

Allarity Therapeutics Announces Dosing of Second Patient in - GlobeNewswire

Jun 27, 2025
pulisher
Jun 25, 2025

Cognition Therapeutics, Inc. Schedules End-of-Phase 2 Meeting with FDA for Alzheimer's Treatment and Files Applications for Breakthrough Status in Dementia with Lewy Bodies - Nasdaq

Jun 25, 2025
pulisher
Jun 24, 2025

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - Business Wire

Jun 24, 2025
pulisher
Jun 23, 2025

Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency - Yahoo Finance

Jun 23, 2025
pulisher
Jun 20, 2025

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO - GlobeNewswire

Jun 20, 2025
pulisher
Jun 17, 2025

$452M Deal: Processa's Phase 2 Gastroparesis Drug Shows Promise, Attracts Major Licensing Interest - Stock Titan

Jun 17, 2025
pulisher
Jun 17, 2025

Processa Pharmaceuticals Signs Binding Term Sheet Granting - GlobeNewswire

Jun 17, 2025
pulisher
Jun 14, 2025

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 - GlobeNewswire

Jun 14, 2025
pulisher
Jun 13, 2025

Layoff Tracker: ADC Therapeutics Cutting 30% of Staff, Closing London Research Facility - BioSpace

Jun 13, 2025
pulisher
Jun 13, 2025

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress - GlobeNewswire

Jun 13, 2025
pulisher
Jun 12, 2025

Celldex Presents Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci Congress 2025 - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance

Jun 12, 2025
pulisher
Jun 11, 2025

Intensity Therapeutics, Inc. Announces Pricing of Public Offering - PR Newswire

Jun 11, 2025
pulisher
Jun 11, 2025

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock - PR Newswire

Jun 11, 2025
pulisher
Jun 11, 2025

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study - Morningstar

Jun 11, 2025
pulisher
Jun 05, 2025

Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-023, a Potential Best-in-Class, Novel CDK4 Selective Inhibitor - Business Wire

Jun 05, 2025
pulisher
Jun 03, 2025

Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire

Jun 03, 2025
pulisher
Jun 02, 2025

Aclaris Therapeutics, Inc. Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Therapeutics Reports Positive Results From The Enlighten 2 Phase 3 Trial Of Lyr-210 - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Allarity Therapeutics Announces First Patient Enrolled in - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer - The Manila Times

Jun 02, 2025
pulisher
Jun 02, 2025

Sapience Therapeutics Provides Data Update from Phase 2 Trial of Lucicebtide in Patients with Glioblastoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - PR Newswire

Jun 02, 2025
pulisher
Jun 02, 2025

Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Actuate Therapeutics Shares Highlights from KOL Event on - GlobeNewswire

Jun 02, 2025
pulisher
Jun 01, 2025

Certain Stock Options of Edgewise Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-JUN-2025. - marketscreener.com

Jun 01, 2025
pulisher
Jun 01, 2025

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology - The Malaysian Reserve

Jun 01, 2025
pulisher
May 31, 2025

Kymera Therapeutics, Inc. (KYMR) to Announce KT-621 Phase 1 Results on June 2, 2025 - Insider Monkey

May 31, 2025
pulisher
May 31, 2025

Xilio Therapeutics Announces Updated Phase 2 Data for - GlobeNewswire

May 31, 2025
pulisher
May 31, 2025

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - Yahoo Finance

May 31, 2025
pulisher
May 29, 2025

Spero Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance

May 29, 2025
pulisher
May 28, 2025

Transposon Announces TPN-101 Selected for Inclusion in the Phase 2/3 HEALEY ALS Platform Trial, Building on the Success of Phase 2 Study in C9orf72-related ALS - PR Newswire

May 28, 2025
pulisher
May 27, 2025

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis - Business Wire

May 27, 2025
pulisher
May 27, 2025

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PR Newswire

May 27, 2025
pulisher
May 23, 2025

Type 2 Diabetes Market to Expand Significantly by 2034, States DelveInsight Report | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - The Globe and Mail

May 23, 2025
pulisher
May 22, 2025

Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025 - Yahoo Finance

May 22, 2025
pulisher
May 21, 2025

Tango Therapeutics, Inc. Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients with MTAP-Deleted Glioblastoma and Other Solid Tumors - marketscreener.com

May 21, 2025

An 2 Therapeutics Inc Azioni (ANTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):